BioSpace· Annalee Armstrong·· 5 hours agoPickScore70
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
In brief
Gilead Sciences will acquire PepStar Therapeutics' IL-23R inhibitor program for a $1.3 billion upfront payment, with the deal expected to close by the end of the quarter. The program's asset, HCXT-2001, is an oral macrocyclic peptide inhibitor. Gilead plans to explore it alone or in combination with emvistegrast in IBD, and to expand into psoriasis.
Why it matters
The deal adds the oral macrocyclic peptide IL-23R inhibitor HCXT-2001 to Gilead's inflammation pipeline and preserves combination exploration with emvistegrast.
Source: BioSpace · biospace.com